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Abstract
The mutant β1,4-galactosyltransferase (β4Gal-T1), β4Gal-T1-Y289L, in contrast to wild-type
β4Gal-T1, can transfer GalNAc from the sugar donor UDP-GalNAc to the acceptor, GlcNAc, with
efficiency as good as that of galactose from UDP-Gal. Furthermore, the mutant can also transfer a
modified sugar, C2 keto galactose, from its UDP derivative to O-GlcNAc modification on proteins
that provided a functional handle for developing a highly sensitive chemoenzymatic method for
detecting O-GlcNAc post-translational modification on proteins. We report herein that the
modified sugar, C2 keto galactose, can be transferred to free GlcNAc residues on N-linked
glycoproteins, such as ovalbumin or asialo-agalacto IgG1. The transfer is strictly dependent on the
presence of both the mutant enzyme and the ketone derivative of the galactose. Moreover, the
PNGase F treatment of the glycoproteins, which cleaves the N-linked oligosaccharide chain,
shows that the modified sugar has been transferred to the N-glycan chains of the glycoproteins and
not to the protein portion. The application of the mutant galactosyltransferase, β4Gal-T1-Y289L,
to produce glycoconjugates carrying sugar moieties with reactive groups, is demonstrated. We
envision a broad potential for this technology such as the possibilities to link cargo molecules to
glycoproteins, such as monoclonal antibodies, via glycan chains, thereby assisting in the
glycotargeting of drugs to the site of action or used as biological probes.
INTRODUCTION
In recent years, it has become evident that a number of biological processes, such as cell
adhesion (1, 2), cell–cell recognition (3), formation of glycosynapses (4, 5), immune defense
(6), targeting, and signaling, appear to be modulated by the glycan moieties of glycoproteins
and glycolipids, where they serve as ligands in the specific protein–carbohydrate (7), lipid–
carbohydrate, and carbohydrate–carbohydrate interactions (5, 8). They also serve as
recognition targets for their complementary binding proteins, the lectins (7). Because of the
molecular diversity of glycans, and being specific recognition ligands in various biological
processes, they are also used to design drugs that target various diseases (9).
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Glycans can be classified as linear or branched sugars. The linear sugars are the
glycosaminoglycans comprising polymers of sulfated disaccharide repeat units that are O-
linked to a core protein, forming a proteoglycan aggregate (10). The branched glycans are
found as N-linked and O-linked sugars on glycoproteins or on glycolipids (11). These
carbohydrate moieties of the linear and branched glycans are synthesized by a super family
of enzymes, the glycosyltransferases, which transfer a sugar moiety from a sugar donor to an
acceptor molecule.
X-ray crystal structures of the catalytic domain of many glycosyltransferases have been
determined in recent years. These studies show that the specificity of the sugar donor is
determined by a few residues in the sugar–nucleotide binding pocket of
glycosyltransferases, which are conserved among family members from different species
(12). This structural information has made it possible to reengineer the existing
glycosyltransferases. For example, the β1,4-galactosyltranferase family in vertebrates
(β4Gal-T1 to T7) is responsible for the transfer of galactose from the donor UDP-galactose
(UDP-Gal) to various glycans in a β1–4 linkage (13, 14). The residue Tyr289 (or Phe) in the
catalytic pocket of β4Gal-T1, determines the sugar donor substrate specificity of the enzyme
toward UDP-Gal (12, 15). Mutation of Tyr289 to Leu or Ile enlarges the binding pocket
such that the mutant enzyme, β4Gal-T1-Y289L, has β1,4-N-acetylgalactosaminyltransferase
(β4GalNAc-T) activity, which is as efficient as its β1,4-galactosyltransferase (β4Gal-T)
activity (15, 16). Similarly, in blood group A GalNAc-transferase, the residues Leu266 and
Gly268, and in blood group B Gal-transferase, the residues Met266 and Ala268 determine
the specificities toward their respective sugar donors, UDP-GalNAc and UDP-Gal (17).
Mutation of Met266 to Leu266 in blood group B Gal-transferase changes the enzyme sugar
donor specificity toward UDP–GalNAc. Furthermore, in β1,3-glucuronyltransferase-1
(GlcA-T1), His 308 (His 311 in GlcAT-P) (18, 19) determines the enzyme specificity
toward the sugar donor UDP–GlcUA. Mutation of His308 to Arg308 changes the specificity
of the sugar donor to UDP–Glc, UDP–Man, or UDP–GlcNAc.
The O-GlcNAc modification on proteins is the dynamic posttranslational modification in
which the β-N-acetylglucosamine is covalently attached to serine or threonine residues in
proteins. Several methods have been reported for the identification of O-GlcNAc
modification on proteins. One of the detection methods involves the enzymatic labeling by
β4Gal-T1 of O-GlcNAc using UDP-3H galactose (20). However, this method is time-
consuming and expensive. The engineered β4Gal-T1-Y289L was shown to transfer from a
UDP derivative, a galactose moiety that has a ketone substitution at the C2 position of the
galactose ring (21). The introduced ketone was then used as a functional handle that allowed
the development of a highly sensitive and rapid chemoenzymatic method to detect O-
GlcNAc modification on proteins (21).
Here, we show that the C2 keto galactose moiety can also be transferred from its UDP
derivative to only free GlcNAc residues on the N-linked glycan chains of ovalbumin or on
asialo-agalacto IgG1 molecules. That the modified galactose is transferred only to the
GlcNAc residues on the N-glycan chains was confirmed by the PNGase F treatment of the
glycoprotein that cleaves the N-linked glycan chains. As previously described (21), the
transfer was followed by coupling the C2 keto galactose moiety on the glycan chain to an
aminooxy biotin which was then detected by a sensitive chemiluminescence assay. Using
this strategy, one can couple two glycoproteins that have modified glycan chains, with each
having reactive functional groups with heterobifunctional linkers (22). The advantage of this
methodology is that the modification occurs in a site-directed manner, only where the
carbohydrate is attached to the glycoprotein. This specificity permits the use of site-directed
immunotherapy without affecting the antigen binding affinity of the immunoglobulin. The
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advantages and potential use of this approach in developing a drug delivery system or a
biological probe are discussed.
EXPERIMENTAL PROCEDURES
Preparation and Purification of Wild-Type β4Gal-T1 and Mutant β4Gal-T1-Y289L
The β4Gal-T1 that has a Cys342 mutated to Thr342 was used as wild-type β4Gal-T1. This
mutation does not affect the enzymatic properties of β4Gal-T1, and it makes the protein
stable at room temperature (15). This wild-type β4Gal-T1 and the mutant β4Gal-T1-Y289L,
derived from the wild type, were constructed in the pET23a vector (Novagen, Inc.) as
described previously (15, 23, 24). The E. coli strain BL21(DE3)pLysS, containing these
plasmids, was used for the expression of these proteins (Novagen, Inc). The recombinant
proteins were expressed in the inclusion body fraction and purified according to the
published method (25). From a liter of induced bacterial culture, the yield of purified
inclusion bodies is generally 80–100 mg. However, the presence of PEG-400 and L-arginine
during folding of the inclusion bodies increases the yields of the native protein, resulting in
an overall folding efficiency of ~60% (25).
Supply of Reagents
The oligosaccharide acceptors, N-acetylglucosamine (GlcNAc), chitobiose (GlcNAcβ1,4-
GlcNAc), and chitotriose (GlcNAcβ1,4-GlcNAcβ1,4-GlcNAc) were obtained from Sigma
Chemicals, U.S.A.; chitotetrose (GlcNAcβ1,4-GlcNAcβ1,4-GlcNAcβ1,4-GlcNAc) and the
pentasaccharide GlcNAcβ1,2-Mana1,6-(GlcNAcβ1,2-Mana1,3)-Man were purchased from
Dextra-labs, U.K. The heptasaccharide tetrapeptide, Arg-[GlcNAcβ1,2-Manα1,6-
(GlcNAcβ1,2-Mana1,3)-Manβ1,4-GlcNAcβ1,4-GlcNAcβ]-Asn-Glu-Gly, which carries both
1,2–1,6-arm and 1,2–1,3-arm linked to core mannose, was purchased from Calbiochem,
U.S.A. The UDP derivative of C2 keto galactose was synthesized as described earlier (21).
The N′-aminooxymethylcarbonylhydrazino-D-biotin (ARP) was purchased from Dojindo
Laboratories. Peptide N-glycosidase F (PNGase F) was obtained from New England Labs.
Albumin from chicken egg white grade VI was purchased from Sigma, and IgG1 was
provided by Drs. Mei-Yun Zhang and Yang Feng from Dr. Dimiter S. Dimitrov’s laboratory
at the Nanobiology program, CCR, NCI.
GalNAc-T Enzyme Assays
The protein concentrations were measured using the Bio-Rad Protein Assay kit on the basis
of the method of Bradford and further verified by SDS-PAGE electrophoresis. An enzymatic
assay procedure for β4Gal-T1 has been reported previously (26). The enzyme activities of
the β4Gal-T1-Y289L mutant were measured using UDP–GalNAc as the sugar nucleotide
donor, and at various concentrations of the acceptors, GlcNAc, chitobiose, chitotriose,
chitotetrose, the mono, di-, tri-, tetrasaccharides, respectively, and the N-linked branched
oligosaccharide structures. For the specific activity measurements, a 100 µL incubation
mixture containing 10 mM MnCl2, 25 mM Tris–HCl, pH 8.0, 500 µM of UDP–GalNAc, 20
ng of the mutant β4Gal-T1-Y289L, and 0.5 µCi 3H-UDP–GalNAc was used for the
GalNAc-T reaction. The reaction was terminated by adding 200 µL of cold water, and the
mixture was passed through a 0.5 mL bed volume column of AG 1-X8 cation resin (Bio-
Rad) to remove any unreacted 3H-UDP–GalNAc. The column was washed successively
with 300, 400, and 500 µL of water, and the column flowthrough was diluted to 20 mL with
Biosafe scintillation fluid; radioactivity was measured with a Beckman counter LS-3801. A
reaction without the acceptor sugar was used as a control.
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Transfer of C2 Keto Galactose from its UDP Derivative to Free GlcNAc Residues on
Glycoacceptors Using the Mutant of β4Gal-T1-Y289L
Albumin from chicken egg white grade VI (40 µg) and recombinant IgG1 (2–5 µg) were
incubated with 1 mM UDP-C2 keto galactose and 500 ng of the mutant β4Gal-T1-Y289L or
488 ng of wild-type β4Gal-T1 in a 10 µL final incubation mixture containing 10 mM MnCl2
and 25 mM Tris–HCl (pH 8.0). Reactions were incubated at 30 °C for 3 h.
Biotinylation of Ovalbumin and IgG1
The ketone-labeled proteins were subsequently diluted to 30 µL in a mixture containing 50
mM NaOAc (pH 3.9) and N-aminooxymethylcarbonylhydrazino-D-biotin (ARP). The
biotinylation reactions were incubated with gentle shaking for 12–16 h at 25 °C. The
reactions were stopped by boiling in Tris-glycine-SDS sample buffer containing β-
mercaptoethanol and analyzed as described (21).
Western Blotting of Ovalbumin and Asialo-Agalacto-IgG1
Proteins were resolved in 14% Tris–glycine gel (Invitrogen) and then transferred by
electrophoresis to nitrocellulose (0.45 µm pore size) for 2 h at 25 V, and biotinylated protein
bands identified as described previously (21). Briefly, the nitrocellulose blots were blocked
for 1 h at room temperature with shaking in a solution containing 5% dry milk in 0.02%
Tween-20. Blots were rinsed thoroughly with water and probed with streptavidin conjugated
with horseradish peroxidase (HRP) (Amersham Biosciences) (1:4000) in 1× PBS pH 7.4,
0.02% Tween-20 containing 3% BSA for 1 h at 25 °C. After probing with the conjugated
streptavidin, the nitrocellulose membranes were washed 4× for 10 min in 5% dry milk
containing 0.02% Tween-20. The streptavidin–HRP signal was visualized by
chemiluminescence after 2 min exposure to ECL detection reagents (Amersham) and
exposure to Kodak Biomax XAR film
Peptide: N-Glycosidase F Treatment
Ovalbumin and asialo-agalacto-IgG1 samples, approximately 3 µg each, were boiled for 10
min in 1% SDS and 1% β-mercaptoethanol. Samples were then incubated in the presence or
absence of PNGase F (2500 units) for 16 h at 37 °C in a buffer containing 5 mM sodium
phosphate and 1% NP-40. Samples were then boiled in SDS-PAGE loading buffer and then
resolved by SDS-PAGE.
MALDI Mass Spectrometric Analyses of Oligosaccharides
An Applied Biosystems Voyager-DE Pro time-of-flight mass spectrometer was utilized for
analyses. The accelerating voltage was 20 kV, guide wire 0.05%, and grid voltage 94%. The
instrument was operated in linear mode under positive ion conditions. A nitrogen laser was
used at 337 nm with 150 laser shots averaged per spectrum. 2,5-Dihydroxybenzoic acid
(Aldrich Chemicals, St. Louis, MO) was used as the matrix for all experiments. The matrix
concentration was 20 mg/mL in water. Sample preparation was a modified “dried droplet”
procedure, whereby 0.3 µL of sample was spotted onto the MALDI target, followed by 0.3
µL of matrix. The mixture was then allowed to air-dry prior to analysis. Calibration was
performed using instrument default settings, and data analysis was carried out using Data
Explorer software residing on the Voyager mass spectrometer
MALDI Mass Spectrometric Analyses of the N-Glycans of Ovalbumin
Albumin from chicken egg white (grade VI), 1 mg in 100 µL deionized water, was washed
in a microcon YM-10 centrifugal filter device with 1.5 mL of deionized water to remove
free oligosaccharide chains. The washed sample was concentrated and incubated at 30 °C
for 18 h in a 100 µL final incubation mixture containing 0.5 mM UDP–GalNAc, 2 µg of the
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mutant β4Gal-T1-Y289L, 10 mM MnCl2, and 25 mM Tris–HCl (pH 8.0). The samples were
then digested for 18 h at 37 °C with 2500 units of PNGase F (NEB) in 50 mM sodium
phosphate buffer. The digested samples were applied onto a Microcon YM-10 filter device,
and the filtrate containing the released N-glycans was analyzed by mass spectrometry as
described above
RESULTS
Sugar Donor Specificity of β4Gal-T1
Our laboratory previously showed that the sugar donor specificity of β4Gal-T1 toward
UDP–Gal is determined by a single amino acid, Tyr, at position 289 (15). When Tyr289 is
mutated to Leu, the sugar donor specificity of β4Gal-T1 is broadened in a way that, in
contrast to the wild-type enzyme which lacks GalNAc-T activity, the mutant β4Gal-T1-
Y289L exhibits both β4Gal-T and β4GalNAc-T activities (15). The Tyr289 mutant can also
transfer from the UDP derivatives the galactose moiety that has, at the C2 position,
substitutions other than the 2-N-acetyl group (–NH–CO–CH3 in GalNAc) (21). Here, we
first investigated the transfer of GalNAc to N-glycans of glycoproteins by the mutant
enzyme, β4Gal-T1-Y289L
Transfer Preferences of β4Gal-T1-Y289L to oligosaccharide acceptors
In a previous study from our laboratory, we had shown by double substrate kinetics that the
true Km for both chitobiose and chitotriose was nearly the same (27), suggesting that the
presence of an additional GlcNAc residue in chitotriose, not present in chitobiose, did not
affect the ground-state binding of these acceptor substrates to the enzyme. Moreover, the
apparent Km values for chitobiose and chitotriose were similar to the true Km values
obtained by double substrate kinetics. In this study, we tested the amount of acceptor
converted to product for various linear and branched structures (Table 1) In the linear
structures, 25 nmol of the acceptor GlcNAc was available in the reaction, and in the
branched structures with two terminal GlcNAc residues, 50 nmol of the acceptor GlcNAc
was available in the reaction mixture. The linear acceptors, mono-, di-, tri- and
tetrasaccharides, all showed 97% to 100% conversion of the acceptor to product (Table 1).
Both chitobiose and chitotriose showed 99% conversion. In the pentasaccharide,
GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-Man, and the heptasaccharide tetrapeptide,
Arg-[GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Mana1,3)-Manβ1,4-GlcNAcβ1,4-GlcNAcβ]-
Asn-Glu-Gly (which carries GlcNAc on both the 1,2–1,6-arm and the 1,2–1,3-arm linked to
core mannose), GalNAc is only transferred to 50% of the available GlcNAc residues on
these acceptor substrates (Table 1).
Transfer of GalNAc Residue to N-Linked Glycoproteins
Over 20 years ago, it was shown β4Gal-T1 could transfer galactose from UDP–Gal to
ovalbumin in the absence of α-lactalbumin (28). Only recently, the permissive mutant
β4Gal-T1-Y289L was shown to transfer GalNAc from UDP–GalNAc to GlcNAc residues
(15). Galactosyltransferase and N-acetylgalactosaminyltransferase assays with the β4Gal-
T1-Y289L mutant, using ovalbumin as the acceptor, were performed by a radiochemical
assay as described previously (15, 25). The kinetics of transfer of GalNAc to ovalbumin was
analyzed over a period of 20 h as described in the Materials and Methods section (Figure 1).
Due to the heterogeneity observed with commercial ovalbumin preparations (29), the
amount of available acceptor substrate is variable, and we show that, after overnight
incubation, only 37% of acceptor is converted into product (Table 1).
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MALDI Mass Spectra Determination of Glycans before and after Treatment with UDP–
GalNAc and UDP-C2 Keto-Modified Galactose
The transfer of GalNAc and C2 keto-modified galactose from their respective UDP
derivatives was followed by MALDI mass profiling (Figure 2). In the MALDI profile, in the
range between m/z 700 and 1500, a unique peak at m/z 853.4 corresponds to the
chitotetrose, prior to the transfer of the donor sugar (Figure 2A). Transfers of GalNAc
(Figure 2B) and C2 keto-modified galactose (Figure 2C) are observed as peaks at m/z
1056.4 and 1055.5, respectively. The MALDI profile in a range between m/z 1099.4 and
3501.0 (Figure 2D) shows a major peak at m/z 1773.4 corresponding to the heptasaccharide
tetrapeptide, Arg-[GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-Manβ1,4-GlcNAcβ1,4-
GlcNAcβ]-Asn-Glu-Gly. The addition of GalNAc (Figure 2E) and C2-keto galactose
(Figure 2F) to either antenna of the heptasaccharide is observed as peaks at m/z 1976.7 and
1975.4, respectively. Under the conditions used in this experiment (Materials and Methods
section), the transfer of GalNAc to the GlcNAc residue on one of the antenna of the
biantennary structure was observed.
MALDI Mass Spectra Determination of N-Linked Carbohydrates from Ovalbumin
To determine the nature of the N-glycans attached to ovalbumin, glycans were released with
PNGase F, purified on amicon filters, and analyzed by MALDI. In the MALDI profile,
obtained from the released N-glycan chains of ovalbumin, peaks in the range between m/z
999.0 and 2400.0 were observed. Four major peaks were found at m/z 1136.4, 1542.7,
1747.0, and 1949.8 (Figure 3A). These are mainly bi- to penta-antennary structures which
lack the terminal sialic acid and galactose present on N-glycans of mammalian proteins.
Upon transfer of GalNAc to one antenna of the penta-antennary structures, the peaks
observed at m/z 1340.5, 1746.4, 1950.0, and 2154.1 correspond to structures with one
additional monosaccharide unit, the GalNAc residue that has been transferred from UDP–
GalNAc by the mutant enzyme β4Gal-T1-Y289L (Figure 3B).
Detection of GlcNAc Residue on Glycosylated Proteins by β4Gal-T1-Y289L
Figure 4 shows the schematics of the transfer of C2 keto galactose to the N-glycan moiety of
a glycoprotein. The ketone moiety at the C2 position of galactose is a flexible chemical
handle, which under mild conditions can be coupled to aminooxy-containing ligands (Figure
4B). When a biotinylated derivative of the aminooxy-containing ligand (N-
(aminooxyacetyl)-N′-(D-biotinoyl) hydrazine) was used as a coupling agent, the transfer and
coupling reaction could be followed by detecting the biotinylated product by
chemiluminescence with streptavidin conjugated to horseradish peroxidase (HRP) (Figure
4C).
Transfer of C2 Keto Galactose from its UDP Derivative to GlcNAc Residues on the Glycan
Chains of Ovalbumin and Asialo-Agalacto-IgG1 by the Mutant Enzyme β4Gal-T1-Y289L and
Coupling of Aminooxy biotin to the Modified Sugar
The mutant enzyme, β4Gal-T1-Y289L, can transfer the C2 keto galactose from its UDP
derivative to the GlcNAc residue on the N-glycan chain of ovalbumin (Figure 5A) or to an
asialo-agalacto-IgG1 molecule (Figure 6A). The transfer of the modified sugar by the
mutant enzyme is carried out at 30 °C for 3 h. Reactions were also performed in the absence
of UDP donor (Figure 5B). The transfer has been followed by coupling to the ketone group
at the C2 position of galactose, the biotinylated aminooxy ligand, followed by resolving
proteins by SDS-PAGE analysis, transfer of proteins to nitrocellulose filters by Western
blotting, and probing by streptavidin–HRP techniques. The transfer is strictly dependent on
the presence of the donor and the mutant enzyme, as observed by the strong
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chemiluminescence of the transferred material (Figure 5B). The wild-type enzyme cannot
utilize the C2 ketone derivative of the galactose (Figure 5B).
Peptide: N-Glycosidase F (PNGase F) Treatment Removes N-Glycan Chains with Modified
Sugar on Glycoproteins
The biotinylated aminooxy ligand is linked only to the N-glycan chain of ovalbumin or
IgG1, as shown by PNGase F treatment, which removes N-glycan chains from the protein.
No chemiluminescence was detected at ovalbumin or IgG1 protein bands in the Western blot
analysis, suggesting that the transferred C2 keto-modified galactose was linked only to the
released carbohydrate moiety (Figures 5C and 6B).
DISCUSSION
This study has shown that it is possible to modify free GlcNAc residues on two N-linked
glycoproteins, ovalbumin and immunoglobulin, by enzymatic methods. These modifications
have only been possible due to the availability of the structural information of
glycosyltransferases which helped to design mutant enzymes that can transfer unnatural
sugar donors (15, 21, 30). Here, we show that the transfer is strictly dependent on the
presence of both the mutant enzyme β4Gal-T1-Y289L and the ketone derivative of the
galactose, while the wild-type enzyme cannot transfer the galactose with the C2 ketone
moiety. We also show that the modifications occur only at the N-glycan chains of the
glycoproteins, as indicated by PNGase F treatment.
The results of the transfer of 3H-labeled GalNAc by β4Gal-T1-Y289L to several linear and
N-linked branched oligosaccharides concur with the results obtained by the MALDI mass
spectral analysis. Also, the results obtained by the chemoenzymatic method are consistent
with the MALDI mass spectral analysis. The efficiency of transfer of GalNAc to various
linear oligosaccharide acceptors was nearly 100%. The length of the oligosaccharide
acceptor did not affect the transfer efficiency of GalNAc. However, when branched
oligosaccharide acceptors are used in the enzymatic assay, the efficiency of transfer of
GalNAc is reduced. Comparison of the MALDI profiles before and after addition of
GalNAc and C2 keto galactose indicated that only one molecule of GalNAc is transferred to
one of the two GlcNAc residues available for the transfer on the pentasaccharide,
GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-Man and the heptasaccharide tetrapeptide,
Arg-[GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-Manβ1,4-GlcNAcβ1,4-GlcNAcβ]-
Asn-Glu-Gly. Both enzymatic and MALDI analysis showed that GalNAc is transferred to
only 50% of the available GlcNAc residues in the branched structures. This may be
explained by the results of a previous work from our laboratory using kinetic and
crystallographic analysis, which showed that, at lower concentrations, the 1,2–1,6-arm of a
biantennary N-glycan is a preferred antenna for galactosylation by β4Gal-T1 (27). In
contrast, at higher concentrations, the 1,2–1,3-arm of a biantennary N-glycan is a preferred
antenna for galactosylation (unpublished results).
When the acceptor is ovalbumin, the transfer efficiency is reduced to 37%. This can be
explained by the known structural variability of N-glycans on ovalbumin preparations as has
been previously observed (29). The largest ovalbumin structure found by MALDI mass
spectral analysis was a galactosylated hybrid glycan of composition
(Man)3(GlcNAc)7(GalNAc)1 (2154.1 m/z; see Figure 3B).
Having demonstrated the labeling of ovalbumin by enzymatic and MALDI mass analysis,
we explored the sensitivity of the chemoenzymatic approach for the detection of N-linked
modifications on ovalbumin. This chemoenzymatic method enabled the detection of N-
linked modifications within minutes using as little as 5 ng of ovalbumin and 10 ng of IgG1.
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This study also shows the possibility of modifying the single N-linked glycosylation site at
Asn297 on the Fc domain of IgG1. Although some glycosylation may occur outside the Fc
domain, this is usually a rare event (31). The glycans that are linked to Asn297 of IgG1 have
been characterized on the basis of the number of terminal galactoses into three groups,
IgG1-G2, IgG1-G1, and IgG1-G0 (32). In the IgG1-G0, the glycans do not have terminal
galactose residues, but instead have terminal GlcNAc residues, as in the heptasaccharide
tetrapeptide used in this study. Only 5% to 14% of the total serum IgG1 is fully sialylated
(32, 33), and generally, IgG1-G2, IgG1-G1, and IgG1-G0 fractions are present in 16%, 35%,
and 35% of the total IgG glycan pool, respectively (32). Here, we show that the C2 keto
galactose moiety can be transferred from its UDP derivative to the free GlcNAc residues on
the N-linked glycan chains of the IgG1 molecules. The transfer was followed by coupling
the ketone handle to an aminooxy biotin, which was then detected by a sensitive
chemiluminescence assay (21).
The method of coupling a target agent to a carrier protein via glycan chains, as described
here using ovalbumin and IgG1 as model systems, offers an advantage over other cross-
linking methods. Here, the target agent is linked in a site-directed manner, only where the
carbohydrate is attached to the glycoprotein, as in the IgG1 molecule at the Fc domain, away
from the antigen binding site. The problem common to previous approaches using
monoclonal antibodies for immunotherapy is the lack of specificity of the reactions,
resulting in heterologous labeling and a decrease in the antibody affinity for the antigen.
The currently described method also represents a sensitive and effective approach to monitor
the glycosylation of therapeutic glycoproteins and monoclonal antibodies. The potential of
glycosyltransferase mutants to produce glycoconjugates carrying sugar moieties with
reactive groups may be a benefit to the glycotargeting of drugs to their site of action. The
role of glycotargeting in the internalization of drugs has been established by numerous
studies (34, 35) since the discovery of the asialoglycoprotein receptor (36); however, much
of its potential remains unexplored. Although a great number of pharmaceutical agents are
discovered each year, the clinical application of these is many times hindered because of
failure to reach the site of action. Our approach using mutant glycosyltransferases to transfer
chemically reactive sugar residues for linking of other molecules via specific glycan chains
has the potential for development of an efficient drug delivery system. A word of caution is
that there is still the challenge to up-scale the production of chimeric proteins needed in
pharmaceutical settings.
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(A) Enzyme kinetics activity of the mutant enzyme, β4Gal-T1-Y289L, with UDP–GalNAc
as a donor substrate and ovalbumin as a glycoprotein acceptor substrate. GalNAc-T activity
was measured using 500 µM UDP–GalNAc and 0.5 mg of ovalbumin in 100 µL incubation
mix containing Mn2+ and Tris pH 8.0 (Material and Methods section). The mutant enzyme
was used at a final concentration of 40 µg/mL, and activity was measured at the indicated
times. For MS analysis, the reaction was carried out for a period of 20 h at 30 °C. (B) The
insert shows the results of the kinetic analysis between zero and 200 min of incubation time.
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MALDI mass spectra of glycans after the transfer of GalNAc to the sugar acceptors
chitotetrose GlcNAcβ1,4-GlcNAcβ1,4-GlcNAcβ1,4-GlcNAcβ (A,B,C) and a
heptasaccharide tetrapeptide Arg-[GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-
Manβ1,4-GlcNAcβ1,4-GlcNAcβ]-Asn-Glu-Gly (D,E,F). Major peaks are annotated with the
carbohydrate structure shown in the symbols for monosaccharides, according to the
nomenclature adopted by the consortium for functional glycomics, http://
www.functionalglycomics.org/static/consortium/. GlcNAc (blue squares), mannose (green
spheres), GalNac (yellow squares), and C2 keto galactose (yellow sphere). The symbols
were drawn using the GlycoWorkbench program found in the eurocarb database http://
www.eurocarbdb.org/. The transferred C2 keto galactose moiety in panels C and F is shown.
Panel A shows a peak at 853.4 m/z corresponding to the linear glycan structure chitotetrose.
Panel B shows a shift in the molecular mass from the starting ion at 853.4 m/z to a peak of
1056.4 m/z after addition of a GalNAc moiety (Material and Methods section). Panel C
shows chitotetrose with the transferred C2 keto galactose moiety to the terminal GlcNAc
residue. Panel D shows a peak at 1773.4 m/z corresponding to the starting branched
heptasaccharide peptide structure, Arg-[GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-
Manβ1,4-GlcNAcβ1,4-GlcNAcβ]-Asn-Glu-Gly. Panel E shows a peak at 1976.7 m/z that
corresponds to a heptasaccharide peptide having one added GalNAc moiety. Panel F shows
the peak at 1975.4 m/z that corresponds to a heptasaccharide to which one C2-keto galactose
moiety has been transferred to one of the available terminal GlcNAc moieties.
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MALDI mass spectra of the glycans released from chicken ovalbumin. After PNGase F
treatment of chicken ovalbumin, the released oligosaccharides were passed through the
microcon YM-10 columns and analyzed by MALDI mass spectrometry. Only the peaks of
interest are annotated, showing their molecular mass and possible structures. Carbohydrate
structures are shown in symbol form, as described in the Figure 2 legend. (A) Glycans
released from the commercial sample (Sigma) of chicken ovalbumin before GalNAc
transfer. Ions at 1136.4, 1542.7, 1747.0, and 1949.8 m/z are assigned to ovalbumin
structures reported (29). (B) Glycan structures released from chicken ovalbumin after the
transfer of GalNAc from UDP–GalNAc with the mutant enzyme β4Gal-T1-Y289L. Ions at
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1340.5, 1746.4, 1950.0, and 2154.1 m/z are assigned to structures in the ovalbumin
preparation onto which GalNAc moieties have been transferred.
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Detection of GlcNAc glycosylated proteins by β4Gal-T1-Y289L. Strategy for the detection
of a terminal GlcNAc residue in the N-linked glycoprotein by the mutant β4Gal-T1-Y289L.
(A) In contrast to the wild-type β4Gal-T1, the mutant enzyme β4Gal-T1-Y289L transfers to
the GlcNAc residues of the N-linked glycoprotein a Gal moiety, from the UDP derivative,
that has modifications located at the C2 position of galactose, such as the N-acetyl moiety
(GalNAc) (15) or a ketone moiety (21). (B) The C2 ketone moiety of the substituting group
in galactose can then be coupled with aminooxy derivatives under mild conditions (21). (C)
When aminooxy biotin (N-(aminooxyacetyl)-N′-(D-biotinoyl) hydrazine) is used as the
coupling agent, the product can be labeled by streptavidin conjugated to horseradish
peroxidase (HRP) and detected by a sensitive chemiluminescence method.
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Transfer of the C2 keto derivative of galactose to free GlcNAc residues on the N-glycan
chains of ovalbumin by the mutant enzyme β4Gal-T1-Y289L and the chemoenzymatic
detection of the transferred C2 keto derivative. (A) N-Glycan chain, attached to ovalbumin,
has been shown using the symbols for monosaccharides as described in Figure 2. The C2
keto galactose (yellow spheres) is transferred to the GlcNAc residues (blue squares) at the
nonreducing end of the glycan chain, by the mutant enzyme β4Gal-T1-Y289L. The mannose
residues in ovalbumin are shown as the green spheres. An arrow shows the cleavage site for
PNGase F. (B) Detection of the transferred C2 keto galactose is accomplished by linking
with the aminooxy biotin, followed by the chemiluminescence technique. After the transfer
of the sugar moiety by the transferase enzyme and subsequent linking to the aminooxy
biotin, the mixtures were resolved by SDS-PAGE, transferred by Western blot to
nitrocellulose membranes, and probed with streptavidin–HRP. In the absence of the sugar
donor substrate (−), little signal was detected using either the wild-type enzyme β4Gal-T1 or
the mutant enzyme β4Gal-T1-Y289L. The chemiluminescence was detected only in the
samples that contained UDP-C2 keto galactose, mutant enzyme (+), and at least 5 ng of
ovalbumin. The wild-type enzyme, β4Gal-T1, having Tyr at position 289, cannot transfer
the modified C2 keto galactose. (C) PNGase F treatment of the biotinylated ovalbumin.
Ovalbumin samples, after the transfer of the modified C2 keto galactose, were treated with
PNGase F (Materials and Methods section), which removes the N-glycan chains from the
protein. In contrast to untreated samples (−), in the PNGase F-treated samples (+) no
chemiluminescence was detected, showing that the transfer of the modified C2 keto
galactose is selective for the glycan portion of ovalbumin.
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Coupling to IgG via N-glycan chains. Selective labeling of the asialo-IgG1 molecule
confirmed by PNGase F treatment. (A) Schematic diagram of an IgG molecule with the N-
glycan structures attached at the Fc region. (B) The C2 keto galactose moiety was
transferred to the carbohydrate in the Fc region of IgG1, using the mutant enzyme β4Gal-
T1-Y289L. Mixtures were either treated without PNGase F (−) or with PNGase F (+)
containing NP-40, prior to the coupling to aminooxy biotin. The mixtures were resolved by
SDS-PAGE, transferred by Western blot to nitrocellulose membranes, and probed with
streptavidin–HRP. No chemiluminescence was detected in PNGase F treated sample (+),
showing that the transfer of the modified C2 keto galactose moiety is selective for the glycan
portion of IgG1 and glycosylation has occurred in the heavy chain of IgG1 at the free
GlcNAc residues (10, 25, and 50 ng).
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GlcNAc 24.90 24.90 24.09 ± 0.07 96.74
β-benzyl-GlcNAc 25.00 25.00 24.50 ± 0.22 98.00
chitobiose 25.00 25.00 24.78 ± 0.21 99.12
chitotriose 25.00 25.00 24.90 ± 0.05 99.60
chitotetraose 25.00 25.00 24.88 ± 0.02 99.52
pentasaccharideb 25.00 50.00 24.50 ± 0.5 49.00c
heptasaccharideb 25.00 50.00 24.68 ± 0.04 49.36c
ovalbumin 24.00 variabled 9.00 ± 14 37.50e
aGalactosyltransferase assays with GalNAc were performed as described in the Materials and Methods section. The mutant β4Gal-T1-Y289L was
assayed at a final concentration of 24 µg/mL. Assays were done at 30 °C with overnight incubations using 1.5 mM of UDP-GalNAc and 1 mM of
acceptors.
b
The pentasaccharide substrate,GlcNAcβ1,2-Manα1,6(GlcNAcβ1,2-Manα1,3)Man, and the heptasaccharide tetrapeptide substrate, Arg-
[GlcNAcβ1,2-Manα1,6-(GlcNAcβ1,2-Manα1,3)-Manβ1,4-GlcNAcβ1,4-GlcNAcβ]-Asn-Glu-Gly, are branched structures which have 2 mol of
GlcNAc per mole of substrate available for the transfer reaction.
cGalNAc is transferred to only 50% of the available GlcNAc residues in the branched substrate structures.
dOvalbumin also has a branched N-linked glycan. The amount of GlcNAc available for transfer is variable.
e
Percentage of the acceptor converted to product has been calculated on the basis of the amount of ovalbumin used in the assay.
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